First Horizon Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

First Horizon Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-24	Closed	-$160	–	2470
2025 Q1	$160	Hold	24	–	–	﹤0.01%	2282
2024 Q4	$301	Hold	24	–	–	﹤0.01%	2235
2024 Q3	$443	Hold	24	–	–	﹤0.01%	2241
2024 Q2	$516	Hold	24	–	–	﹤0.01%	2202
2024 Q1	$646	Hold	24	–	–	﹤0.01%	2198
2023 Q4	$719	Hold	24	–	–	﹤0.01%	2267
2023 Q3	$491	Sell	24 -28	-54%	-$509	﹤0.01%	2315
2023 Q2	$1.03K	Hold	52	–	–	﹤0.01%	2259
2023 Q1	$890	Hold	52	–	–	﹤0.01%	2290
2022 Q4	$1.02K	Buy	+52	New	+$958	﹤0.01%	2237

Other funds holding RCKT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

First Horizon Advisors's RCKT Position: Q2 2025 in Review

First Horizon Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 24 shares — an estimated $160 sold.

First Horizon Advisors first reported a position in RCKT in Q4 2022 and held it in 10 quarters. The position peaked at $1.03K in Q2 2023. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

First Horizon Advisors reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
First Horizon Advisors sold 24 Rocket Pharmaceuticals shares in Q2 2025, an estimated $160.
First Horizon Advisors first reported a position in Rocket Pharmaceuticals in Q4 2022 and held it in 10 quarters.
First Horizon Advisors's Rocket Pharmaceuticals position peaked at $1.03K in Q2 2023.
196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.